Research powered investment banking
Home
Research
Companies
Find Alpha
Themes
Top Picks
Premium
Transactions
Events
Redeye
At a Glance
Our Culture
Investor Services
Corporate Broking
Certified Adviser
Corporate Finance
Newsroom
The Team
Careers
FAQ
Governance
Members network
Community
sign in
Home
research
Companies
Find Alpha
Themes
Top Picks
Transactions
Events
redeye
About
At a Glance
Our Culture
Investor Services
Corporate Broking
Certified Adviser
Corporate Finance
Newsroom
The Team
Careers
FAQ
Governance
Community
Company overview

IDL Biotech: Showing progression in line with investment case

Redeye Research Update timeStamp 2019/08/23

We provide a short research update with the latest financial estimates and valuation following IDL Biotech’s Q2’19 report. We factor in higher gross margins and slightly lower costs related to SG&A in near-term, which has a positive effect on our valuation. Our new base case amounts to SEK 3.8 per share, with a Bull and Bear Case of SEK 7.4 and 1.5 per share, respectively.

Download research report

Ludvig Svensson

Equity Analyst

Does IDL Biotech have great people behind it? Find out now:
Visit Stock Insight
Tagged companies

You need to be a Redeye member to access this content

Become a member to:

By clicking "Sign up" you indicate that you read and agree to our Terms & Conditions